There are inherent risks in biotech investing. A decade’s worth and often hundreds of millions of dollars in R&D, along with binary risks of failed clinical trials or regulatory approval. Above and ...

By Dennis Thompson HealthDay ReporterTHURSDAY, April 9, 2026 (HealthDay News) — Prompt treatment with a fecal transplant can ...

C. diff is a horrible disease that can cause significant morbidity. It can and often does recur and kills around 30,000 Americans every year. We have made progress in prevention and treatment, but ...

Researchers at the American Society for Microbiology’s 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy have reported that low-dose antibiotic treatments appear to be as effective ...

Fecal microbiota transplantation has become one of the most effective treatments for recurrent Clostridioides difficile infections, but its long-term role in gastroenterology may hinge on moving ...

The antibiotic vancomycin, recommended as first-line treatment for infection caused by the deadly superbug C. difficile (C. diff), may not be living up to its promise, according to new research. The ...

Current guidelines recommend using either metronidazole or vancomycin to treat C. diff infections. “For many years the two antibiotics were considered to be equivalent in their ability to cure C. diff ...

Charles Darkoh, Ph.D., a researcher at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health, was recently awarded a five-year, $1.9 million R01 grant by the ...

Clostridium difficile bacteria, computer illustration. C. difficile is a normal inhabitant of the human intestine, but it can become a pathogen when antibiotics disrupt the normal intestinal flora and ...

Christian John Lillis, cofounder and executive director of the Peggy Lillis Foundation for C difficile Education & Advocacy, explained how FDA-approved microbiome-based therapeutics help to treat and ...

After reporting non-statistically significant results in it a phase-II study, Cambridge, Mass.-based Seres Therapeutics is launching a revised phase-II study for its SER-109 Clostridium Difficile ...

SALT LAKE CITY – Over the past two decades there has been a sharp rise in the number and severity of infections caused by the bacteria Clostridium difficile often shortened to C. diff now the most ...